# Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures

> **NCT01721317** · PHASE4 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 6 (actual)

## Conditions studied

- Seizures

## Interventions

- **DRUG:** Ezogabine/Retigabine IR
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01721317
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12-19
- **Primary completion:** 2013-06-20
- **Final completion:** 2013-06-20
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** After reevaluation of the benefit: risk profile of ezogabine/retigabine, GSK does not believe the early adjunctive treatment study population is appropriate.
- **Last updated:** 2020-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01721317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01721317, "Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT01721317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*